Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel IBAT inhibitors in early development at AstraZeneca

Oct. 26, 2004

Several series of PPAR agonists presented by Aventis researchers

Oct. 26, 2004

New data on the pharmacokinetics and effects of topical testosterone in women

Oct. 25, 2004

Nobex and Biocon to develop oral insulin product for diabetes

Oct. 25, 2004

Enrollment begins in INITIATE plus study of NovoLog Mix 70/30

Oct. 25, 2004

New glucokinase activators emerge from Banyu R&D

Oct. 25, 2004

RUP3 receptor as a target for diabetes and obesity

Oct. 25, 2004

New oxytocin antagonists identified by ARS team

Oct. 25, 2004

CTCE-0214 enters phase I studies for stem cell mobilization

Oct. 25, 2004

Merck researchers elucidate tissue selective agonism of SARM SA-766

Oct. 22, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...